Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2021

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
Single arm study with dose escalation Phase Ib cohort followed by a Phase II cohort. PAC-1 (PO) will be given daily on Days 1 through 21 of each cycle (28-day cycle). Entrectinib (PO) will be given daily on Days 1 through 28 of each cycle. Response will be evaluated after every 2 cycles. Treatment will continue until disease progression based on RECIST criteria or intolerable toxicity.
Epistemonikos ID: 2d883ba070481fd2967d41ed379428349fe17506
First added on: May 07, 2024